论文部分内容阅读
乳腺癌作为世界范围内女性最常见的癌症类型,医生通常给予患者手术、化疗、放疗、内分泌等治疗,但肿瘤治疗的耐药性却也是普遍存在的。表观遗传过程控制着癌症的发生、发展,因此肿瘤发生与基因表达的表观遗传调控相关的机制、基因和信号通路的研究就备受人们关注。鉴于组蛋白去乙酰化酶(histone deacetylase,HDAC)对染色质重塑和表观遗传学有着深远的影响,其抑制剂自然成为研究热点。本文主要就组蛋白去乙酰化酶抑制剂(histone deacetylase inhibitors,HDACIs)在乳腺癌治疗中的临床研究进展进行综述。
Breast cancer, the most common type of cancer in women worldwide, is usually given to patients undergoing surgery, chemotherapy, radiotherapy, endocrinology and so on, but resistance to cancer treatment is also prevalent. Epigenetic processes control the occurrence and development of cancer. Therefore, the mechanisms of tumor epigenetic regulation of gene expression, genes and signaling pathways have attracted much attention. Histone deacetylase (HDAC) has a profound impact on chromatin remodeling and epigenetics, and its inhibitors have naturally become a research hotspot. This review summarizes the clinical progress of histone deacetylase inhibitors (HDACIs) in the treatment of breast cancer.